Hongya Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hongya Chen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Masri
Knight Cardiovascular Institute, Oregon Health and Science University
4 shared publications - Daniel Kamna
Knight Cardiovascular Institute, Oregon Health and Science University
3 shared publications Hailey Volk
Knight Cardiovascular Institute, OHSU
3 shared publications- Olives Nguyen
Oregon Health & Science University
3 shared publications Angelica T. Mejia
Knight Cardiovascular Institute, OHSU
2 shared publicationsIngy Mahana
Knight Cardiovascular Institute, OHSU
2 shared publications
Latest Publications
- Open Access
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e042488
Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy
Background: Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy. Methods: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified. Results: We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55–73]). Patients were followed for a median of 3037.0 days (IQR, 2808–3221) before mavacamten initiation and for 240 days (IQR, 117–407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new‐onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow‐up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n=80, 26%), AF (n=74, 24%), and AFL (n=16, 5%)). Predictors of outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack/stroke claim) were age at mavacamten start, obesity, transient ischemic attack/stroke history, and residence in the Western versus Southern United States. Conclusions: Over an 8‐month median follow‐up on mavacamten in patients with obstructive hypertrophic cardiomyopathy, new AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to better understand the expected incidence of AF/AFL, HF, and other long‐term outcomes of mavacamten treatment in obstructive hypertrophic cardiomyopathy.
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e042488
Open AccessCharacteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy
Background: Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy. Methods: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified. Results: We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55–73]). Patients were followed for a median of 3037.0 days (IQR, 2808–3221) before mavacamten initiation and for 240 days (IQR, 117–407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new‐onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow‐up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n=80, 26%), AF (n=74, 24%), and AFL (n=16, 5%)). Predictors of outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack/stroke claim) were age at mavacamten start, obesity, transient ischemic attack/stroke history, and residence in the Western versus Southern United States. Conclusions: Over an 8‐month median follow‐up on mavacamten in patients with obstructive hypertrophic cardiomyopathy, new AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to better understand the expected incidence of AF/AFL, HF, and other long‐term outcomes of mavacamten treatment in obstructive hypertrophic cardiomyopathy.
- Open Access
Characteristics and Outcomes of Mavacamten Use In 2440 Patients with Obstructive Hypertrophic Cardiomyopathy
Aims: To assess real-world characteristics, outcomes, and healthcare utilization associated with commercial mavacamten use in patients with oHCM. Methods and Results: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified and individual hospital-level claims manually reviewed to categorize cardiovascular hospitalizations. We included 2,440 patients and 18,494 mavacamten dispenses (63% females, median age 66 years [Interquartile range (IQR): 55, 73]). Patients were followed for a median of 3,037.0 days (IQR: 2,808, 3,221) prior to mavacamten initiation, and for 240 days (IQR: 117, 407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, while new-onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow-up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n= 80, 26%), AF (n=74, 24%), and AFL (n= 16, 5%)). Predictors of safety outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack [TIA]/stroke claim) were: age at mavacamten start, obesity, and TIA/stroke history. Conclusion: With 8 month median follow-up in this study, healthcare utilization for patients on mavacamten appeared substantial. New AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to understand longer-term outcomes of mavacamten use in oHCM.
Open AccessCharacteristics and Outcomes of Mavacamten Use In 2440 Patients with Obstructive Hypertrophic Cardiomyopathy
Aims: To assess real-world characteristics, outcomes, and healthcare utilization associated with commercial mavacamten use in patients with oHCM. Methods and Results: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified and individual hospital-level claims manually reviewed to categorize cardiovascular hospitalizations. We included 2,440 patients and 18,494 mavacamten dispenses (63% females, median age 66 years [Interquartile range (IQR): 55, 73]). Patients were followed for a median of 3,037.0 days (IQR: 2,808, 3,221) prior to mavacamten initiation, and for 240 days (IQR: 117, 407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, while new-onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow-up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n= 80, 26%), AF (n=74, 24%), and AFL (n= 16, 5%)). Predictors of safety outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack [TIA]/stroke claim) were: age at mavacamten start, obesity, and TIA/stroke history. Conclusion: With 8 month median follow-up in this study, healthcare utilization for patients on mavacamten appeared substantial. New AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to understand longer-term outcomes of mavacamten use in oHCM.
- Open Access
- 7 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (6) , e038758
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy
Background: Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic profile and clinical outcomes for mavacamten and aficamten, 2 cardiac myosin inhibitors investigated in symptomatic hypertrophic cardiomyopathy. Methods and Results: Using a systematic search, 10 clinical trials with safety and efficacy data for either drug in obstructive hypertrophic cardiomyopathy (oHCM) and nonobstructive hypertrophic cardiomyopathy were included. Additionally, we included data from regulatory agencies. Both drugs demonstrated substantial benefit in reducing left ventricular outflow tract obstruction (Valsalva left ventricular outflow tract gradients improved by −45 mm Hg or better), symptom burden (placebo‐corrected New York Heart Association class improvement ≥1 of at least 30%), and cardiac biomarkers (geometric mean ratio of 0.2 for N‐terminal pro‐B‐type natriuretic peptide) while improving exercise parameters (improved placebo‐corrected peak oxygen consumption of at least 1.4 to 1.8 mL/kg per minute) in patients with oHCM. Both drugs were generally well‐tolerated, although patients on mavacamten had higher rates of treatment interruption (partly protocol‐driven, 8.7% versus 0.5%, respectively, in oHCM) due to left ventricular ejection fraction reduction, atrial fibrillation (11.5 versus 4.1 per 100 patient‐years, respectively, in oHCM), and heart failure (1.7 versus 0.0 per 100 patient‐years, respectively, in oHCM) compared with aficamten. These comparisons are limited by a shorter exposure duration to aficamten, and longer follow‐up is needed. The data in nonobstructive hypertrophic cardiomyopathy are derived from phase II trials, with phase III trials ongoing. Conclusions: Mavacamten and aficamten represent effective medications for the treatment of symptomatic oHCM.
- 7 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (6) , e038758
Open AccessSafety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy
Background: Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic profile and clinical outcomes for mavacamten and aficamten, 2 cardiac myosin inhibitors investigated in symptomatic hypertrophic cardiomyopathy. Methods and Results: Using a systematic search, 10 clinical trials with safety and efficacy data for either drug in obstructive hypertrophic cardiomyopathy (oHCM) and nonobstructive hypertrophic cardiomyopathy were included. Additionally, we included data from regulatory agencies. Both drugs demonstrated substantial benefit in reducing left ventricular outflow tract obstruction (Valsalva left ventricular outflow tract gradients improved by −45 mm Hg or better), symptom burden (placebo‐corrected New York Heart Association class improvement ≥1 of at least 30%), and cardiac biomarkers (geometric mean ratio of 0.2 for N‐terminal pro‐B‐type natriuretic peptide) while improving exercise parameters (improved placebo‐corrected peak oxygen consumption of at least 1.4 to 1.8 mL/kg per minute) in patients with oHCM. Both drugs were generally well‐tolerated, although patients on mavacamten had higher rates of treatment interruption (partly protocol‐driven, 8.7% versus 0.5%, respectively, in oHCM) due to left ventricular ejection fraction reduction, atrial fibrillation (11.5 versus 4.1 per 100 patient‐years, respectively, in oHCM), and heart failure (1.7 versus 0.0 per 100 patient‐years, respectively, in oHCM) compared with aficamten. These comparisons are limited by a shorter exposure duration to aficamten, and longer follow‐up is needed. The data in nonobstructive hypertrophic cardiomyopathy are derived from phase II trials, with phase III trials ongoing. Conclusions: Mavacamten and aficamten represent effective medications for the treatment of symptomatic oHCM.
- Open Access
- 5 April 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (7) , e023895
Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer
Advancement in the diagnosis and treatment of transthyretin amyloid cardiomyopathy has made great strides in recent years. Novel therapeutics for transthyretin amyloidosis such as tafamidis, patisiran, and inotersen have shown significant benefits in a not‐so‐rare disease but come with high listing price tags ranging from a quarter to more than a half million dollars per year. These costs create significant financial barriers for the majority of patients, especially those with existing Medicare insurance plans. Of 72 patients reviewed, 67% were Medicare beneficiaries. Financial assistance was explored for the majority, and 37 (51%) patients with Medicare Part D received financial assistance that reduced their copayments to $0. Only one‐third of our patients were able to afford these medications without any forms of financial assistance. Of these patients, 4 (6%) had the highest copayments ranging from $13 000 to $15 000 per year. To navigate the complexities of prescribing and affordability in amyloidosis, a multidisciplinary team including a dedicated clinical pharmacist is crucial in guaranteeing patients’ success to secure these novel therapeutics. In this article, we discuss our experiences with prescribing, acquiring insurance authorizations, and financing these life‐saving medications based on patient‐specific insurance plans and socioeconomic status.
- 5 April 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (7) , e023895
Open AccessNavigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer
Advancement in the diagnosis and treatment of transthyretin amyloid cardiomyopathy has made great strides in recent years. Novel therapeutics for transthyretin amyloidosis such as tafamidis, patisiran, and inotersen have shown significant benefits in a not‐so‐rare disease but come with high listing price tags ranging from a quarter to more than a half million dollars per year. These costs create significant financial barriers for the majority of patients, especially those with existing Medicare insurance plans. Of 72 patients reviewed, 67% were Medicare beneficiaries. Financial assistance was explored for the majority, and 37 (51%) patients with Medicare Part D received financial assistance that reduced their copayments to $0. Only one‐third of our patients were able to afford these medications without any forms of financial assistance. Of these patients, 4 (6%) had the highest copayments ranging from $13 000 to $15 000 per year. To navigate the complexities of prescribing and affordability in amyloidosis, a multidisciplinary team including a dedicated clinical pharmacist is crucial in guaranteeing patients’ success to secure these novel therapeutics. In this article, we discuss our experiences with prescribing, acquiring insurance authorizations, and financing these life‐saving medications based on patient‐specific insurance plans and socioeconomic status.